BrainStorm spikes on NurOwn data in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) said a single dose of its NurOwn stem cell therapy slowed at least one measure of disease progression in 11 of 12 of patients in a Phase IIa trial to treat ALS.

The company said the autologous mesenchymal stromal cells slowed the decline in ALS Functional Rating Score-Revised (ALSFRS) by 45%, from 1.41 points per month during the run-in period to 0.78 points per month at three months and 0.6 points per month at six months. ...